Dr. Panagiotis Konstantinopoulos, MD

Dr. Konstantinopoulos practices at Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute.

Dr. Konstantinopoulos' NPI, 1649218942, was assigned on June 2, 2006. Dr. Konstantinopoulos graduated from University of Patras School of Medicine in 1997. Dr. Konstantinopoulos' Massachusetts license number on file is 224086.

Dr. Konstantinopoulos' primary practice is Dana-Farber Cancer Institute, at 450 Brookline Avenue, Boston, MA 02115.

Dr. Konstantinopoulos' primary practice is Dana-Farber Cancer Institute in Boston, Massachusetts, part of Dana-Farber Cancer Institute. Dr. Konstantinopoulos is also affiliated with Brigham and Women's Hospital. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Konstantinopoulos to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Konstantinopoulos practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Konstantinopoulos' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Konstantinopoulos is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Konstantinopoulos' licenses on file in 3 states: Massachusetts, Florida and New Hampshire.

Dmand AI lists prostate cancer among the conditions Dr. Konstantinopoulos treats.

CMS data shows 248 Medicare services from Dr. Konstantinopoulos across 3 procedure codes in 2024, for 103 Medicare patients. Medicare paid $18,943 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 103 Medicare patients who saw Dr. Konstantinopoulos in 2024. The largest group is 65 to 74, with 49 patients. 75% of them have high cholesterol, and 62% have cancer. 15% are also on Medicaid. Their average risk score is 2.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Konstantinopoulos' median patient age at 70, with 99% women.

In 2024, Dr. Konstantinopoulos wrote 134 Medicare Part D claims for 49 patients. 63% of them were for generic drugs. CMS names the drug for 62 of them, across 4 drugs with 11 or more claims each, at $486,984 in total drug cost. In 2023, CMS named 284 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Konstantinopoulos for performance year 2024, reported as part of a group. Dr. Konstantinopoulos accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Konstantinopoulos as offering telehealth.

Dmand AI links 227 papers to Dr. Konstantinopoulos, published from 2002 to 2025. 2019 was the busiest year, with 16. The most frequent topics are Ovarian Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Poly(ADP-ribose) Polymerase Inhibitors. Dr. Konstantinopoulos has published most often in Gynecol Oncol. Dr. Konstantinopoulos' most frequent co-authors are Elizabeth Stover, MD, PhD, Richard T. Penson, MD and Alexi Anne Wright, MD.

Dmand AI links Dr. Konstantinopoulos to 15 clinical trials, 9 of them phase 2 studies. 8 are still active or recruiting. Conditions studied include Fallopian Tube Diseases, Fallopian Tube Neoplasms and Endometrial Neoplasms. National Cancer Institute (NCI) sponsors the most, 8.

CMS Open Payments shows 112 general payments to Dr. Konstantinopoulos from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 83% of the total. AstraZeneca Pharmaceuticals LP paid the most, $46,115. It also lists 3 research payments totaling $202,629 from 2023 to 2024.

Dmand AI lists 1 award for Dr. Konstantinopoulos, most recently CMS Stage 1 2012 in 2012.

Dr. Konstantinopoulos graduated from University of Patras School of Medicine in 1997. Dr. Konstantinopoulos is a member of ASCO.

Dr. Konstantinopoulos is in network with 11 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.